
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2126563/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. Scientific Reports, 2015, 5, 13079.	3.3	332
2	Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cellate cells. Hepatology, 2005, 42, 1339-1348.	7.3	310
3	Liver fibrosis: from the bench to clinical targets. Digestive and Liver Disease, 2004, 36, 231-242.	0.9	294
4	Fibrosis in chronic liver diseases: diagnosis and management. Journal of Hepatology, 2005, 42, S22-S36.	3.7	212
5	A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology, 1999, 29, 858-867.	7.3	192
6	Glutathione Levels Discriminate between Oxidative Stress and Transforming Growth Factor-β Signaling in Activated Rat Hepatic Stellate Cells. Journal of Biological Chemistry, 1999, 274, 33881-33887.	3.4	139
7	Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver International, 2014, 34, 834-843.	3.9	132
8	MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation. Hepatology, 2018, 68, 172-186.	7.3	129
9	Urea cycle dysregulation in non-alcoholic fatty liver disease. Journal of Hepatology, 2018, 69, 905-915.	3.7	123
10	Endoplasmic reticulum stress enhances fibrosis through <scp>IRE</scp> 1αâ€mediated degradation of miRâ€150 and <scp>XBP</scp> â€1 splicing. EMBO Molecular Medicine, 2016, 8, 729-744.	6.9	122
11	Peroxisome proliferator-activated receptor-Î ² signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology, 2003, 124, 184-201.	1.3	120
12	FAK controls the mechanical activation of YAP, a transcriptional regulator required for durotaxis. FASEB Journal, 2018, 32, 1099-1107.	0.5	117
13	Trichostatin A, a Histone Deacetylase Inhibitor, Suppresses Collagen Synthesis and Prevents TGF-β1-Induced Fibrogenesis in Skin Fibroblasts. Experimental Cell Research, 2002, 278, 184-197.	2.6	116
14	Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis. Scientific Reports, 2019, 9, 7299.	3.3	99
15	Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut, 2004, 53, 1180-1189.	12.1	95
16	Liver tissue engineering: From implantable tissue to whole organ engineering. Hepatology Communications, 2018, 2, 131-141.	4.3	94
17	Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology, 2004, 39, 97-108.	7.3	89
18	Role of the stromal-derived factor-1 (SDF-1)–CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. Journal of Hepatology, 2012, 57, 813-820.	3.7	82

#	Article	IF	CITATIONS
19	Dual Targeting of Histone Methyltransferase G9a and DNAâ€Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology, 2019, 69, 587-603.	7.3	81
20	Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. Journal of Hepatology, 2016, 64, 823-833.	3.7	80
21	Rapid production of human liver scaffolds for functional tissue engineering by high shear stress oscillation-decellularization. Scientific Reports, 2017, 7, 5534.	3.3	79
22	Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. Journal of Hepatology, 2003, 38, 564-572.	3.7	74
23	Neuroendocrine tumors and fibrosis: An unsolved mystery?. Cancer, 2017, 123, 4770-4790.	4.1	70
24	Fibrosis in alcoholic and nonalcoholic steatohepatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 231-244.	2.4	63
25	Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 874-892.	7.3	62
26	Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. Journal of Hepatology, 2002, 37, 788-796.	3.7	61
27	Activation of p38MAPK mediates the angiostatic effect of the chemokine receptor CXCR3-B. International Journal of Biochemistry and Cell Biology, 2008, 40, 1764-1774.	2.8	60
28	All-trans and 9-cis retinoic acid alter rat hepatic stellate cell phenotype differentially. Gut, 1999, 45, 134-142.	12.1	58
29	PPARÎ ² regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation. Journal of Lipid Research, 2003, 44, 280-295.	4.2	58
30	Molecular Mechanisms of Hepatic Fibrosis in Non-Alcoholic Steatohepatitis. Digestive Diseases, 2010, 28, 229-235.	1.9	49
31	Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo. Cancer Letters, 2013, 333, 244-252.	7.2	46
32	Impaired LXRα Phosphorylation Attenuates Progression of Fatty Liver Disease. Cell Reports, 2019, 26, 984-995.e6.	6.4	46
33	Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology, 2003, 124, 504-520.	1.3	45
34	Engineering in vitro models of hepatofibrogenesis. Advanced Drug Delivery Reviews, 2017, 121, 147-157.	13.7	45
35	Tamoxifen mechanically deactivates hepatic stellate cells via the G protein-coupled estrogen receptor. Oncogene, 2019, 38, 2910-2922.	5.9	43
36	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	12.1	42

#	Article	IF	CITATIONS
37	Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition. Cells, 2020, 9, 83.	4.1	41
38	A Microphysiological System for Studying Nonalcoholic Steatohepatitis. Hepatology Communications, 2020, 4, 77-91.	4.3	41
39	Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. American Journal of Physiology - Renal Physiology, 2011, 301, G210-G219.	3.4	39
40	CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression. Gut, 2018, 67, 348-361.	12.1	37
41	Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. British Journal of Pharmacology, 2001, 134, 224-232.	5.4	36
42	Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. Gut, 2021, 70, gutjnl-2019-320205.	12.1	36
43	Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling. Journal of Biological Chemistry, 2017, 292, 18961-18972.	3.4	34
44	Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis. Medical Hypotheses, 2018, 113, 91-97.	1.5	34
45	MARCKS is a downstream effector in platelet-derived growth factor-induced cell motility in activated human hepatic stellate cells. Experimental Cell Research, 2008, 314, 1444-1454.	2.6	28
46	Inhibiting IRE1α-endonuclease activity decreases tumor burden in a mouse model for hepatocellular carcinoma. ELife, 2020, 9, .	6.0	27
47	The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. Fibrogenesis and Tissue Repair, 2013, 6, 17.	3.4	26
48	Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells. British Journal of Pharmacology, 2005, 146, 77-88.	5.4	24
49	TGF-β 1-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, 882-895.	3.7	24
50	Decellularized Human Gut as a Natural 3D Platform for Research in Intestinal Fibrosis. Inflammatory Bowel Diseases, 2019, 25, 1740-1750.	1.9	21
51	Effect of aldosterone on collagen steady state levels in primary and subcultured rat hepatic stellate cells. Journal of Hepatology, 2001, 34, 230-238.	3.7	20
52	MARCKS actin-binding capacity mediates actin filament assembly during mitosis in human hepatic stellate cells. American Journal of Physiology - Cell Physiology, 2012, 303, C357-C367.	4.6	20
53	Nuclear localization of TRK-A in liver cells. Histology and Histopathology, 2008, 23, 327-40.	0.7	20
54	Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. American Journal of Physiology - Renal Physiology, 2006, 290, G120-G128.	3.4	19

#	Article	IF	CITATIONS
55	Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis. Cells, 2019, 8, 1409.	4.1	17
56	Hexa Histidine–Tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species. Hepatology, 2021, 73, 2527-2545.	7.3	17
57	DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer. Cancer Research, 2021, 81, 2861-2873.	0.9	15
58	Determination and Characterization of Tetraspanin-Associated Phosphoinositide-4 Kinases in Primary and Neoplastic Liver Cells. Methods in Molecular Biology, 2016, 1376, 203-212.	0.9	15
59	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Scientific Reports, 2017, 7, 5514.	3.3	14
60	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2246-2256.	3.8	14
61	The adenosine monophosphate–activated protein kinase—vacuolar adenosine triphosphatase–pH axis: A key regulator of the profibrogenic phenotype of human hepatic stellate cells. Hepatology, 2018, 68, 1140-1153.	7.3	13
62	Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH. Cells, 2020, 9, 1237.	4.1	13
63	Optimization and Validation of a Novel Three-Dimensional Co-Culture System in Decellularized Human Liver Scaffold for the Study of Liver Fibrosis and Cancer. Cancers, 2021, 13, 4936.	3.7	13
64	Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. JHEP Reports, 2022, 4, 100444.	4.9	13
65	Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro. Free Radical Biology and Medicine, 2017, 102, 162-173.	2.9	11
66	Clinicopathological correlations of mesenteric fibrosis and evaluation of a novel biomarker for fibrosis detection in small bowel neuroendocrine neoplasms. Endocrine, 2020, 67, 718-726.	2.3	10
67	Targeting the muscle for the treatment and prevention of hepatic encephalopathy. Journal of Hepatology, 2016, 65, 876-878.	3.7	8
68	Transcriptomic Profiling of In Vitro Tumor-Stromal Cell Paracrine Crosstalk Identifies Involvement of the Integrin Signaling Pathway in the Pathogenesis of Mesenteric Fibrosis in Human Small Intestinal Neuroendocrine Neoplasms. Frontiers in Oncology, 2021, 11, 629665.	2.8	7
69	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers, 2020, 12, 3748.	3.7	6
70	Effect of somatostatin-14 on extracellular matrix expression by activated rat hepatic stellate cells. Journal of Hepatology, 2001, 34, 6.	3.7	5
71	Design of a Gene Panel to Expose the Versatile Role of Hepatic Stellate Cells in Human Liver Fibrosis. Pharmaceutics, 2020, 12, 278.	4.5	5
72	AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. American Journal of Physiology - Renal Physiology, 2021, 320, G543-G556.	3.4	5

KRISTA ROMBOUTS

#	Article	IF	CITATIONS
73	Hepatic Stellate Cell Culture Models. , 2015, , 15-27.		4
74	Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension. Gut, 2015, 64, 523-524.	12.1	4
75	Early increase in ammonia is a feature of non-alcoholic fatty liver disease and the ammonia lowering drug, ornithine phenylacetate (OCR-002) prevents progression of fibrosis in a rodent model. Journal of Hepatology, 2017, 66, S170.	3.7	4
76	Erratum to "Liver fibrosis: from the bench to clinical targets―[Dig. Liver Dis. 36 (2004) 231–242]. Digestive and Liver Disease, 2004, 36, 562-563.	0.9	3
77	Identification of somatostatin receptors in human cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 2002, 36, 84.	3.7	2
78	Early Increase in Ammonia Is A Feature of Non-Alcoholic Fatty Liver Disease and the Ammonia Lowering Drug, Ornithine Phenylacetate (OCR002) Prevents Progression of Fibrosis in A Rodent Model. Journal of Clinical and Experimental Hepatology, 2017, 7, S73-S74.	0.9	2
79	Development of human liver extracellular matrix hydrogel for three dimensional cell culture and cell transplantation. Journal of Hepatology, 2017, 66, S339.	3.7	2
80	Ammonia: A novel target for the prevention of NAFLD progression in NASH. Journal of Hepatology, 2018, 68, S359-S360.	3.7	2
81	PS-036-Optimization and validation of a novel three-dimensional co-culture system in decellularized human liver scaffold for the study of liver fibrosis and cancer. Journal of Hepatology, 2019, 70, e24.	3.7	2
82	PS-209-Whole Human liver decellularisation-recellularisation for future liver transplantation and extracorporeal device application. Journal of Hepatology, 2019, 70, e139.	3.7	2
83	P8 3D BIOLOGICAL SCAFFOLDS OBTAINED FROM DISCARDED HUMAN LIVERS AS A PLATFORM FOR TISSUE ENGINEERING AND REGENERATIVE MEDICINE. Journal of Hepatology, 2014, 60, S69.	3.7	1
84	P0437 : Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro. Journal of Hepatology, 2015, 62, S477.	3.7	1
85	P0423 : Role of apoptic DNA and extracellular core histones in inflammasome activation in primary human hepatic stellate cells. Journal of Hepatology, 2015, 62, S472.	3.7	1
86	Genotype-Phenotype Analysis across 130,422 Genetic Variants Identifies Rspo3 as the First Genome-Wide Significant Modifier Gene in Primary Sclerosing Cholangitis. Journal of Hepatology, 2016, 64, S642-S643.	3.7	1
87	Handling of Activation Status of Human Hepatic Stellate Cells by Low-Molecular-Weight FGF2 via the Induction of Cytoglobin. Journal of Hepatology, 2016, 64, S711.	3.7	1
88	Extracellular matrix turnover is regulated in 3D disease-specific human liver scaffolds engineered with human hepatic stellate cells. Journal of Hepatology, 2017, 66, S143.	3.7	1
89	A function for PPAR- \hat{I}^2 in rat stellate cell activation. Journal of Hepatology, 2000, 32, 31.	3.7	0
90	Heterogeneity in rat hepatic PPAR-α. Journal of Hepatology, 2000, 32, 79.	3.7	0

#	Article	IF	CITATIONS
91	Effect of HMG-COA reductase inhibitors on proliferation and ECM protein synthesis by rat hepatic stellate cells. Journal of Hepatology, 2001, 34, 92.	3.7	0
92	In vivo antifibrogenic effects of histone deacetylase inhibitors. Journal of Hepatology, 2002, 36, 9.	3.7	0
93	PPAR-beta and retinol metabolism related gene-expression in HSC. Journal of Hepatology, 2002, 36, 71.	3.7	0
94	Identification and function of MARCKS in human hepatic stellate cells (HHSC). Journal of Hepatology, 2003, 38, 81-82.	3.7	0
95	16 Identification of a cross talk between the PDCF-beta receptor signalling pathway and the myristoylated alanine-rich PKC substrate (MARCKS) protein in activated human hepatic stellate cells. Journal of Hepatology, 2004, 40, 7.	3.7	0
96	263 In vitro effect of specific somatostatin receptor agonists on human hepatocellular carcinoma. Journal of Hepatology, 2004, 40, 82.	3.7	0
97	Albert Geerts One of the "young boys― Journal of Hepatology, 2009, 50, 843-844.	3.7	0
98	106 MYRISTOYLATED ALANINE RICH PROTEIN KINASE C SUBSTRATE (MARCKS), A FUNDAMENTAL CELL CYCLE REGULATOR OF THE MITOTIC PROCESS IN HUMAN HEPATIC STELLATE CELLS (HHSC). Journal of Hepatology, 2010, 52, S48.	3.7	0
99	868 STROMAL-DERIVED FACTOR-1 (SDF-1) – CXCR4 AXIS HAS AN IMPORTANT ROLE ON THE INTERACTION OF HUMAN HEPATIC STELLATE CELLS (HHSC) AND CC CELL LINES. Journal of Hepatology, 2010, 52, S338.	3.7	0
100	OC-5 Cytoskeletal rearrangement by the mitogen-activated protein kinase ERK5 interferes with the motile and invasive phenotype of hepatocellular carcinoma cells. Digestive and Liver Disease, 2011, 43, S66.	0.9	0
101	206 CYTOSKELETAL REARRANGEMENT BY THE MITOGEN-ACTIVATED PROTEIN KINASE ERK5 INTERFERES WITH THE MOTILE AND INVASIVE PHENOTYPE OF HEPATOCELLULAR CARCINOMA CELLS. Journal of Hepatology, 2011, 54, S87.	3.7	0
102	212 SDF-1 ACTS MORE AS A CHEMOTACTIC AGENT THAN AS A SURVIVAL FACTOR ON THE INTERACTION OF HUMAN HEPATIC STELLATE CELLS (HHSC) AND CCA CELL LINES. Journal of Hepatology, 2011, 54, S89-S90.	3.7	0
103	What is new in the liver sinusoids? meeting report, 16th International Symposium on Cells of the Hepatic Sinusoid (ISCHS). Fibrogenesis and Tissue Repair, 2011, 4, 27.	3.4	0
104	Cholangiocarcinoma (CCA) express chemokine receptor CXCR7: Important role of CXCR7 in mediating CXCL12 induced CCA cells chemotaxis and survival. Digestive and Liver Disease, 2014, 46, e37.	0.9	0
105	P89 HEAT SHOCK FACTOR 1 (HSF1) IS DOWNREGULATED IN RADIOFREQUENCY ABLATED MICE WITH SECONDARY LIVER CANCER PRETREATED WITH NANOLIPOSOMAL shRNA-HSF1. Journal of Hepatology, 2014, 60, S96.	3.7	0
106	The AMPK-related kinase, Nuak2 is modulated by the activation process and regulates motility of hepatic stellate cells (HSC). Digestive and Liver Disease, 2014, 46, e59.	0.9	0
107	P287 HEPATIC C6-CERAMIDE NANOLIPOSOMAL UPTAKE AFFECTS MCD-INDUCED NASH IN VIVO VIA ALTERATIONS IN PROLIFERATIVE, FIBROTIC AND OXIDATIVE STRESS SIGNALING PATHWAYS. Journal of Hepatology, 2014, 60, S161.	3.7	0
108	P428 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE TREATMENT IMPROVES MARKERS OF HEPATIC FUNCTION AND FIBROSIS IN STEATOSIS INDUCED BY HIGH FAT/CARBOHYDRATE DIET. Journal of Hepatology, 2014, 60, S210.	3.7	0

#	Article	IF	CITATIONS
109	P620 THE AMPK-RELATED KINASE, Nuak2 IS MODULATED BY THE ACTIVATION PROCESS AND REGULATES MOTILITY OF HEPATIC STELLATE CELLS (HSC). Journal of Hepatology, 2014, 60, S275-S276.	3.7	0
110	P0281 : Decellularised human liver as a natural scaffold for 3D-disease modelling. Journal of Hepatology, 2015, 62, S412-S413.	3.7	0
111	THE AMPK RELATED KINASE NUAK2 INTERACTS WITH TGF-BETA AND REGULATES THE ACTIVATION PROCESS OF HEPATIC STELLATE CELLS (HSC). Digestive and Liver Disease, 2015, 47, e23.	0.9	0
112	PO283 : Adenosine monophosphate activated kinase (AMPK) in cancer and human hepatic stellate cell crosstalk. Journal of Hepatology, 2015, 62, S414.	3.7	0
113	P0443 : Hyperammonemia activates human hepatic stellate cells and is a target for treatment of portal hypertension. Journal of Hepatology, 2015, 62, S478-S479.	3.7	0
114	The CXCL12/CXCR7 system mediates migration and survival of cholangiocarcinoma (CCA) cells through interaction with CXCR4 and β-arrestin-2. Digestive and Liver Disease, 2016, 48, e13.	0.9	0
115	Mitotic Checkpoint CHK2 Upregulation is Linked to Chromosomal Instability in Human Hepatocellular Carcinoma. Journal of Hepatology, 2016, 64, S331-S332.	3.7	0
116	Mucosa Associated Invariant T Cells are Phenotypically Altered and Functionally Impaired in Patients with Autoimmune Liver Disease. Journal of Hepatology, 2016, 64, S441-S442.	3.7	0
117	Hepatocellular Carcinoma Differentially Modulates AMPK Activity and Induces Autophagy in Hepatic Stellate Cells in a Paracrine Manner. Journal of Hepatology, 2016, 64, S567-S568.	3.7	0
118	The CXCL12/CXCR7 System Mediates Migration and Survival of Cholangiocarcinoma (CCA) Cells through Interaction with CXCR4 and Barrestin-2. Journal of Hepatology, 2016, 64, S555.	3.7	0
119	Elucidating the Biomechanical Response of Human Hepatic Stellate Cells on Substrates Mimicking Healthy and Fibrotic Matrix Rigidity. Journal of Hepatology, 2016, 64, S706.	3.7	0
120	Human Serum Albumin administration prevents cell death-derived extracellular nucleosomes and core-histones-driven inflammasome activation and portal hypertension in Acute on Chronic Liver Failure. Journal of Hepatology, 2017, 66, S579.	3.7	0
121	A new in vitro hepatocellular carcinoma model based on human normal and fibrotic 3D extracellular matrix scaffold bio-engineering. Journal of Hepatology, 2017, 66, S230-S231.	3.7	0
122	Targeting tumour-stromal interactions – differential pharmacological modification of AMPK/mTORC1 in human hepatic stellate cells and hepatocellular carcinoma. Journal of Hepatology, 2017, 66, S461.	3.7	0
123	The vacuolar adenosine tri-phosphatase (v-ATPase) proton pump as therapeutic target in human activated HSC. Journal of Hepatology, 2017, 66, S650.	3.7	0
124	OC.14.1: Development of Decellularised Human GUT as a Natural 3D-Platform for Intestinal Bioengineering. Digestive and Liver Disease, 2017, 49, e116.	0.9	0
125	Chk2 DNA damage response protein mislocalization further enhances chromosomal instability and human hepatocellular carcinoma progression. Journal of Hepatology, 2017, 66, S78.	3.7	0
126	Mucosal-associated invariant T cells are significantly decreased and exhausted in patients with autoimmune liver disease, but promote primary hepatic stellate cell proliferation. Journal of Hepatology, 2017, 66, S35-S36.	3.7	0

#	ARTICLE	IF	CITATIONS
127	The inhibitory effect of ADM on hepatic NF-κB activation in 2D and 3D hepatic cell cultures. Digestive and Liver Disease, 2018, 50, 24.	0.9	0
128	Aspecific ECM composition regulates Smad dependent – TGFbeta1-induced EMT response in HepG2 cells engineered in cirrhotic and healthyliver 3D scaffolds. Journal of Hepatology, 2018, 68, S688.	3.7	0
129	3D bio-printing ofhuman hepatic tissue using human liver extracellular matrix as tissue-specificbioink. Journal of Hepatology, 2018, 68, S55.	3.7	0
130	Epigenetic modification of urea cycle enzymes in NAFLD animal models and patients: Implications for novel therapeutic approaches. Journal of Hepatology, 2018, 68, S359-S360.	3.7	0
131	Primary human HSC cell phenotype is differently regulated by pro-fibrogenic and pro-inflammatory stimuli in cirrhotic and healthy human liver 3D ECM scaffolds. Journal of Hepatology, 2018, 68, S409.	3.7	0
132	Investigating the effect of adrenomedullin on hepatic NF-kB activation by 2D and 3D hepatic cell cultures. Journal of Hepatology, 2018, 68, S134.	3.7	0
133	The paracrine effect of visceraladipose tissue obtained at bariatric surgery on primary human hepatic stellatecells grown in human 3D healthy liver scaffolds. Journal of Hepatology, 2018, 68, S334-S335.	3.7	0
134	THU-447-DNA damage response CHK2 activates senescence cellular program and supports oxidative metabolism to drive hepatocellular carcinoma development. Journal of Hepatology, 2019, 70, e355.	3.7	0
135	THU-064-Identification of new epigenetic targets in hepatic fibrosis. Journal of Hepatology, 2019, 70, e188.	3.7	Ο
136	SAT-397-HIC-5 and GARP expression is upregulated by hydrogen peroxide and TGF beta in primary human hepatic stellate cells cultured on decellularized human liver 3D ECM scaffolds. Journal of Hepatology, 2019, 70, e808.	3.7	0
137	Role of Histone Deacetylases in Transcriptional Control of the Hepatic Stellate Cell Phenotype. , 2003, , 189-205.		0
138	What Causes Desmoplastic Reaction in Small Intestinal Neuroendocrine Neoplasms?. Current Oncology Reports, 2022, , .	4.0	0